Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,totalAssets,commonStock,retainedEarnings,otherAssets,cash,totalCurrentLiabilities,deferredLongTermAssetCharges,propertyPlantEquipment,totalCurrentAssets,netReceivables,inventory,accountsPayable,otherCurrentAssets,intangibleAssets,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToInventory,changeToAccountReceivables,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,currency,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,trailingPE,epsTrailingTwelveMonths,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,exchange,exchangeDataDelayedBy,marketState,twoHundredDayAverageChangePercent,shortName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,market,priceHint,regularMarketChangePercent,regularMarketDayRange,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,fax,industry,address2
t0,IBXNF,7871223.0,24773200,65984,,333555,,333509,409103,904348,429261,429261,,-8961,,,,46,1467665,1038404,563317,-95706,,333509,333509,805804.0,1244222.0,7871223.0,9115445.0,52680158.0,-45614739.0,2125940.0,4210710.0,745971.0,2125940.0,1682715.0,5306790.0,678213.0,300905.0,578095.0,,,-61313,-105774,-58586,-54586,-78342,4000,359304,519664,94681,-55858,280304,6683,-105774,4560819.0,en-US,US,EQUITY,False,Delayed Quote,USD,0.21853,0.0,0.0,0,0,finmb_121266,Other OTC,IBEX Technologies Inc.,CAD,1697,3550,0.12687,1.384137,0.09166 - 0.246,-0.027470008,-0.111666694,0.09166,0.246,1615984200,1615984200,1615984200,4.7506523,0.046,0.317,0.21084303,0.0076869726,0.036458272,0.19172525,0.026804745,4516359,0.6893691,15,America/New_York,EDT,-14400000,False,False,PNK,0,PRE,0.1398081,IBEX TECHNOLOGIES,0.21853,1629832026,0.0,0.21853,0.21853,0.21853,1250,us_market,4,0.0,0.21853 - 0.21853,0.14,,,0.246,0.0917,0.2108,0.1917,1.7k,3.55k,24.77M,,20.76M,26.69%,0.00%,,,,,,,,,,,,,,,,"Jul 30, 2020","Apr 29, 2021",19.21%,15.92%,5.78%,13.67%,5.39M,0.29,-12.60%,2.97M,1.03M,1.04M,0.0460,-46.80%,4.21M,0.17,666.13k,8.46,7.11,0.32,1.63M,2.19M,Value,H4P 1P7,,1,10,"IBEX Technologies Inc., through its subsidiaries, manufactures and markets enzymes for biomedical use in Canada, the United States, the United Kingdom, and internationally. It offers a portfolio of recombinant glycosaminoglycan lyases, including Heparinase I, Heparinase II, Heparinase III, Chondroitinase AC, and Chondroitinase B; cartilage assays for the study of synthesis and degradation of connective tissue components; collagen antibodies; and diamine oxidase liquid. The company also manufactures and markets a range of arthritis assays, which are used in osteoarthritis research. In addition, it provides services, such as filling and lyophilization for making disposable medical device components; and custom fermentation and micro dispensing of enzymes, as well as contract manufacturing. It serves manufacturers of medical devices, quality control labs, and academic research institutions. IBEX Technologies Inc. was founded in 1986 and is based in Montreal, Canada.",Montreal,514 344 4004,QC,1,1609372800,1622505600,1,Canada,http://www.ibex.ca,86400,2,5485 ParE Street,514 344 8827,,Suite 100
t-1,IBXNF,7532664.0,24773200,15147,,248558,,248505,474683,702539,212709,212709,,-10394,,,,53,1312915,1100206,610376,35849,,248505,248505,808654.0,1352191.0,7532664.0,8884855.0,52672258.0,-45948248.0,2125940.0,3851406.0,818439.0,2125940.0,1665325.0,5093590.0,798811.0,245047.0,639408.0,159706.0,,-392871,-18605,-50928,-50928,44909,4000,-309736,-240203,93738,19706,-265867,11677,-18605,4275151.0,en-US,US,EQUITY,False,Delayed Quote,USD,0.21853,0.0,0.0,0,0,finmb_121266,Other OTC,IBEX Technologies Inc.,CAD,1697,3550,0.12687,1.384137,0.09166 - 0.246,-0.027470008,-0.111666694,0.09166,0.246,1615984200,1615984200,1615984200,4.7506523,0.046,0.317,0.21084303,0.0076869726,0.036458272,0.19172525,0.026804745,4516359,0.6893691,15,America/New_York,EDT,-14400000,False,False,PNK,0,PRE,0.1398081,IBEX TECHNOLOGIES,0.21853,1629832026,0.0,0.21853,0.21853,0.21853,1250,us_market,4,0.0,0.21853 - 0.21853,0.14,,,0.246,0.0917,0.2108,0.1917,1.7k,3.55k,24.77M,,20.76M,26.69%,0.00%,,,,,,,,,,,,,,,,"Jul 30, 2020","Apr 29, 2021",19.21%,15.92%,5.78%,13.67%,5.39M,0.29,-12.60%,2.97M,1.03M,1.04M,0.0460,-46.80%,4.21M,0.17,666.13k,8.46,7.11,0.32,1.63M,2.19M,Value,H4P 1P7,,1,10,"IBEX Technologies Inc., through its subsidiaries, manufactures and markets enzymes for biomedical use in Canada, the United States, the United Kingdom, and internationally. It offers a portfolio of recombinant glycosaminoglycan lyases, including Heparinase I, Heparinase II, Heparinase III, Chondroitinase AC, and Chondroitinase B; cartilage assays for the study of synthesis and degradation of connective tissue components; collagen antibodies; and diamine oxidase liquid. The company also manufactures and markets a range of arthritis assays, which are used in osteoarthritis research. In addition, it provides services, such as filling and lyophilization for making disposable medical device components; and custom fermentation and micro dispensing of enzymes, as well as contract manufacturing. It serves manufacturers of medical devices, quality control labs, and academic research institutions. IBEX Technologies Inc. was founded in 1986 and is based in Montreal, Canada.",Montreal,514 344 4004,QC,1,1609372800,1622505600,1,Canada,http://www.ibex.ca,86400,2,5485 ParE Street,514 344 8827,,Suite 100
t-2,IBXNF,7280295.0,24773200,7218,,146060,,150066,512437,632057,112402,112402,,-11235,,,,-4006,1164658,1052256,532601,33658,,150066,150066,804790.0,1788177.0,7280295.0,9068472.0,52672258.0,-46196753.0,2125940.0,4161142.0,1217982.0,2125940.0,1740458.0,5202074.0,644482.0,264753.0,1032279.0,48168.0,,88764,-17500,-46705,-46705,16058,4000,455625,519830,95896,-32035,184412,16669,-17500,3984092.0,en-US,US,EQUITY,False,Delayed Quote,USD,0.21853,0.0,0.0,0,0,finmb_121266,Other OTC,IBEX Technologies Inc.,CAD,1697,3550,0.12687,1.384137,0.09166 - 0.246,-0.027470008,-0.111666694,0.09166,0.246,1615984200,1615984200,1615984200,4.7506523,0.046,0.317,0.21084303,0.0076869726,0.036458272,0.19172525,0.026804745,4516359,0.6893691,15,America/New_York,EDT,-14400000,False,False,PNK,0,PRE,0.1398081,IBEX TECHNOLOGIES,0.21853,1629832026,0.0,0.21853,0.21853,0.21853,1250,us_market,4,0.0,0.21853 - 0.21853,0.14,,,0.246,0.0917,0.2108,0.1917,1.7k,3.55k,24.77M,,20.76M,26.69%,0.00%,,,,,,,,,,,,,,,,"Jul 30, 2020","Apr 29, 2021",19.21%,15.92%,5.78%,13.67%,5.39M,0.29,-12.60%,2.97M,1.03M,1.04M,0.0460,-46.80%,4.21M,0.17,666.13k,8.46,7.11,0.32,1.63M,2.19M,Value,H4P 1P7,,1,10,"IBEX Technologies Inc., through its subsidiaries, manufactures and markets enzymes for biomedical use in Canada, the United States, the United Kingdom, and internationally. It offers a portfolio of recombinant glycosaminoglycan lyases, including Heparinase I, Heparinase II, Heparinase III, Chondroitinase AC, and Chondroitinase B; cartilage assays for the study of synthesis and degradation of connective tissue components; collagen antibodies; and diamine oxidase liquid. The company also manufactures and markets a range of arthritis assays, which are used in osteoarthritis research. In addition, it provides services, such as filling and lyophilization for making disposable medical device components; and custom fermentation and micro dispensing of enzymes, as well as contract manufacturing. It serves manufacturers of medical devices, quality control labs, and academic research institutions. IBEX Technologies Inc. was founded in 1986 and is based in Montreal, Canada.",Montreal,514 344 4004,QC,1,1609372800,1622505600,1,Canada,http://www.ibex.ca,86400,2,5485 ParE Street,514 344 8827,,Suite 100
t-3,IBXNF,7109275.0,24773200,8307,,620165,,303792,714339,826638,103992,103992,,-28343,,,,316373,1446799,1342807,620161,516173,,303792,303792,794241.0,1473535.0,7119680.0,8593215.0,52672258.0,-46346819.0,2125940.0,3705517.0,1109844.0,2125940.0,1541986.0,4914884.0,751300.0,232718.0,943515.0,125762.0,10405.0,341360,1056557,-1020822,-1020822,70529,4000,862387,826652,87549,5328,168237,-159357,-17500,3805040.0,en-US,US,EQUITY,False,Delayed Quote,USD,0.21853,0.0,0.0,0,0,finmb_121266,Other OTC,IBEX Technologies Inc.,CAD,1697,3550,0.12687,1.384137,0.09166 - 0.246,-0.027470008,-0.111666694,0.09166,0.246,1615984200,1615984200,1615984200,4.7506523,0.046,0.317,0.21084303,0.0076869726,0.036458272,0.19172525,0.026804745,4516359,0.6893691,15,America/New_York,EDT,-14400000,False,False,PNK,0,PRE,0.1398081,IBEX TECHNOLOGIES,0.21853,1629832026,0.0,0.21853,0.21853,0.21853,1250,us_market,4,0.0,0.21853 - 0.21853,0.14,,,0.246,0.0917,0.2108,0.1917,1.7k,3.55k,24.77M,,20.76M,26.69%,0.00%,,,,,,,,,,,,,,,,"Jul 30, 2020","Apr 29, 2021",19.21%,15.92%,5.78%,13.67%,5.39M,0.29,-12.60%,2.97M,1.03M,1.04M,0.0460,-46.80%,4.21M,0.17,666.13k,8.46,7.11,0.32,1.63M,2.19M,Value,H4P 1P7,,1,10,"IBEX Technologies Inc., through its subsidiaries, manufactures and markets enzymes for biomedical use in Canada, the United States, the United Kingdom, and internationally. It offers a portfolio of recombinant glycosaminoglycan lyases, including Heparinase I, Heparinase II, Heparinase III, Chondroitinase AC, and Chondroitinase B; cartilage assays for the study of synthesis and degradation of connective tissue components; collagen antibodies; and diamine oxidase liquid. The company also manufactures and markets a range of arthritis assays, which are used in osteoarthritis research. In addition, it provides services, such as filling and lyophilization for making disposable medical device components; and custom fermentation and micro dispensing of enzymes, as well as contract manufacturing. It serves manufacturers of medical devices, quality control labs, and academic research institutions. IBEX Technologies Inc. was founded in 1986 and is based in Montreal, Canada.",Montreal,514 344 4004,QC,1,1609372800,1622505600,1,Canada,http://www.ibex.ca,86400,2,5485 ParE Street,514 344 8827,,Suite 100
